Korea Investment CORP Sells 12,283 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Korea Investment CORP trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 15.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 65,940 shares of the biopharmaceutical company's stock after selling 12,283 shares during the period. Korea Investment CORP owned about 0.06% of Regeneron Pharmaceuticals worth $41,821,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of REGN. GAMMA Investing LLC raised its stake in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after acquiring an additional 814,713 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after buying an additional 810,144 shares in the last quarter. Nuveen LLC bought a new position in Regeneron Pharmaceuticals in the first quarter worth about $343,764,000. Pacer Advisors Inc. raised its stake in Regeneron Pharmaceuticals by 2,296.9% in the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after buying an additional 390,374 shares in the last quarter. Finally, Assenagon Asset Management S.A. raised its stake in Regeneron Pharmaceuticals by 171.0% in the first quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after buying an additional 303,785 shares in the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $8.68 on Friday, hitting $589.48. The company had a trading volume of 1,438,624 shares, compared to its average volume of 1,111,801. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The stock's 50-day simple moving average is $549.27 and its 200 day simple moving average is $592.95. The stock has a market cap of $62.48 billion, a price-to-earnings ratio of 14.86, a P/E/G ratio of 1.97 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3,675,600 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the company posted $11.56 earnings per share. The firm's quarterly revenue was up 3.6% on a year-over-year basis. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a $0.88 dividend. The ex-dividend date is Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on REGN shares. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, August 14th. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Finally, Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus price target of $829.65.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.